Jing Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing Chen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bi Huang
Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, China
2 shared publications - Linfeng Xie
Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publications - Suxin Luo
Department of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, China
2 shared publications - Yuanzhu Li
Department of Cardiology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
2 shared publications - Bryan Richard Sasmita
Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publication - Yuhe Zhao
Department of Cardiology, Chongqing Seventh People's Hospital, Chongqing, China
1 shared publication
Latest Publications
- 1 January 2026
- Published by Elsevier in International Journal of Cardiology
- Vol. 447, 134142
Extracellular water to lean body mass ratio predicts mortality in patients with chronic heart failure: A prospective, observational study
- 1 January 2026
- Published by Elsevier in International Journal of Cardiology
- Vol. 447, 134142
Extracellular water to lean body mass ratio predicts mortality in patients with chronic heart failure: A prospective, observational study
- 5 May 2025
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (2) , 505-515
Magnesium Sulfate in Cardiogenic Shock Patients: A Retrospective Propensity Score-Matched Cohort Study
Purpose Magnesium ions are essential inorganic ions in the body, playing a crucial role in normal physiological functions. Previous studies have shown that supplementing magnesium sulfate can provide survival advantages for critically ill patients. Our study aimed to explore whether intravenous magnesium sulfate could provide a survival advantage in patients with cardiogenic shock (CS). Methods This is a retrospective cohort study based on the Medical Information Mart in Intensive Care (MIMIC) IV database. The study participants were CS patients. The study endpoints were 30-day, 90-day, and 360-day all-cause mortality. The external validation was performed in the eICU 2.0 database. Results The pre-matched and propensity score-matched (PSM) cohorts included 2547 and 830 patients, respectively. In the overall patient cohort, multivariable Cox regression showed that magnesium supplementation was associated with a reduced risk of 30-day (HR 0.635; 95% CI 0.539, 0.749; p < 0.001), 90-day (HR 0.687; 95% CI 0.591, 0.749; p < 0.001), and 360-day all-cause mortality (HR 0.681; 95% CI 0.593, 0.782; p < 0.001). This association remained consistent after PSM in 30-day (HR 0.624; 95% CI 0.506, 0.768; p < 0.001), 90-day (HR 0.640; 95% CI 0.530, 0.774; p < 0.001), and 360-day all-cause mortality (HR 0.629; 95% CI 0.529, 0.749; p < 0.001). Subgroup analysis found that the effect of the magnesium supplement was consistent in different subgroup patients, including in patients with hypomagnesemia versus non-hypomagnesemia (all p-interaction > 0.05). In 1867 CS patients from eICU 2.0 for external validation, after PSM, intravenous magnesium sulfate use was associated with lower in-hospital (HR 0.742; 95% CI 0.578, 0.952; p = 0.019) and in-ICU all-cause mortality (HR 0.729; 95% CI 0.555, 0.958; p = 0.023). Conclusion Intravenous magnesium sulfate use was associated with reduced risk of all-cause mortality in patients with CS, and this benefit was not affected by patients’ serum magnesium levels. Prospective studies are warranted to verify this finding.
- 5 May 2025
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (2) , 505-515
Magnesium Sulfate in Cardiogenic Shock Patients: A Retrospective Propensity Score-Matched Cohort Study
Purpose Magnesium ions are essential inorganic ions in the body, playing a crucial role in normal physiological functions. Previous studies have shown that supplementing magnesium sulfate can provide survival advantages for critically ill patients. Our study aimed to explore whether intravenous magnesium sulfate could provide a survival advantage in patients with cardiogenic shock (CS). Methods This is a retrospective cohort study based on the Medical Information Mart in Intensive Care (MIMIC) IV database. The study participants were CS patients. The study endpoints were 30-day, 90-day, and 360-day all-cause mortality. The external validation was performed in the eICU 2.0 database. Results The pre-matched and propensity score-matched (PSM) cohorts included 2547 and 830 patients, respectively. In the overall patient cohort, multivariable Cox regression showed that magnesium supplementation was associated with a reduced risk of 30-day (HR 0.635; 95% CI 0.539, 0.749; p < 0.001), 90-day (HR 0.687; 95% CI 0.591, 0.749; p < 0.001), and 360-day all-cause mortality (HR 0.681; 95% CI 0.593, 0.782; p < 0.001). This association remained consistent after PSM in 30-day (HR 0.624; 95% CI 0.506, 0.768; p < 0.001), 90-day (HR 0.640; 95% CI 0.530, 0.774; p < 0.001), and 360-day all-cause mortality (HR 0.629; 95% CI 0.529, 0.749; p < 0.001). Subgroup analysis found that the effect of the magnesium supplement was consistent in different subgroup patients, including in patients with hypomagnesemia versus non-hypomagnesemia (all p-interaction > 0.05). In 1867 CS patients from eICU 2.0 for external validation, after PSM, intravenous magnesium sulfate use was associated with lower in-hospital (HR 0.742; 95% CI 0.578, 0.952; p = 0.019) and in-ICU all-cause mortality (HR 0.729; 95% CI 0.555, 0.958; p = 0.023). Conclusion Intravenous magnesium sulfate use was associated with reduced risk of all-cause mortality in patients with CS, and this benefit was not affected by patients’ serum magnesium levels. Prospective studies are warranted to verify this finding.